Concepedia

Publication | Closed Access

A Pilot Study of Subcutaneous Recombinant Hirudin (HBW 023) in the Treatment of Deep Vein Thrombosis

DOI

45

Citations

0

References

1994

Year

François Schiele, Alain Vuillemenot, P Kramarz, Y Kieffer, J Soria, Claudine Soria, A. Camez, Mc. Mirshahi, Jean‐Pierre Bassand
Thrombosis and Haemostasis

Abstract

Subcutaneous administration of recombinant hirudin ensures prolonged stable plasma levels of recombinant hirudin which results in efficient anticoagulation. A dose-ranging study conducted with subcutaneous recombinant hirudin in comparison to conventional heparin therapy may answer the question as to efficacy.